Dravet Syndrome Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Eisai, Stoke Therapeutics, EpyGenix Therapeutic, Marinus Pharma, Stoke Therapeutics, Jazz Pharma

The Key Dravet Syndrome Companies in the market include - Takeda, Eisai, Stoke Therapeurtics, EpyGenix Therapeutics, Marinus Pharmaceuticals, Stoke Therapeutics, Inc, Zogenix International Ltd, Inc., Jazz Pharmaceuticals, Ovid Therapeutics Inc., Longboard Pharmaceuticals, and others.

DelveInsight's "Dravet Syndrome Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Dravet Syndrome, historical and forecasted epidemiology as well as the Dravet Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Dravet Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dravet Syndrome Market Forecast [https://www.delveinsight.com/sample-request/dravet-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Dravet Syndrome Market Report:

*
The Dravet Syndrome market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In January 2025, Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on restoring protein expression through RNA-based medicine, has reached an agreement with global regulatory agencies on the design of its Phase 3 EMPEROR study. This trial aims to evaluate zorevunersen as a potential first disease-modifying treatment for Dravet syndrome.

*
In January 2025, The FDA awarded rare pediatric disease designation to relutrigine, a therapy developed by Praxis Precision Medicines for Dravet syndrome. This treatment is designed to help reduce seizures in children with epileptic disorders such as Dravet syndrome.

*
In December 2024, Stoke Therapeutics, Inc. announced that the FDA has granted Breakthrough Therapy Designation to zorevunersen for treating Dravet syndrome in patients with a confirmed SCN1A gene mutation that is not linked to gain-of-function.

*
In February 2024, The FDA has approved Encoded Therapeutics' investigational new drug (IND) application for ETX101, allowing the company to initiate clinical trials for this gene therapy candidate aimed at treating Sodium channel protein type 1 subunit alpha (SCN1A)+ Dravet syndrome. Additionally, Australia's TGA has granted approval under its Clinical Trial Approval (CTA) scheme for the trial to begin. ETX101 is an AAV9-mediated gene regulation therapy designed to enhance SCN1A gene expression in GABAergic inhibitory interneurons, targeting the root cause of Dravet syndrome. Encoded plans to launch a two-part Phase I/II clinical trial called ENDEAVOR in the US for patients aged six months to under three years in the first half of this year.

*
A new US epidemiological study, according to the Dravet Syndrome Foundation (2022), found that the prevalence of Dravet Syndrome, which affects 1:15,700 infants and 80% of whom had a SCN1A mutation, is twice as high as previously thought

*
The predicted total number of diagnosed cases of Dravet Syndrome in France in 2022 was 1,050, and by 2032, that number is expected to rise

*
It is projected that there will be approximately 1,000 treated instances of Dravet syndrome in the UK in 2022, and that number will rise by 2032

*
As to the company's declaration, FINTEPLA's net product sales amounted to around $75 million. In a similar vein, EPIDIOLEX's net product sales in 2021 totaled $463.6 million.

*
A number of the newly developed Dravet syndrome treatments are in the late stages of clinical testing. These include lorcaserin and TAK-935 (soticlestat), both of which have demonstrated great promise in trials

*
Key Dravet Syndrome Companies: Takeda, Eisai, Stoke Therapeurtics, EpyGenix Therapeutics, Marinus Pharmaceuticals, Stoke Therapeutics, Inc, Zogenix International Ltd, Inc., Jazz Pharmaceuticals, Ovid Therapeutics Inc., Longboard Pharmaceuticals, and others

*
Key Dravet Syndrome Therapies: TAK-935 (soticlestat), BELVIQ (lorcaserin), STK-001, ganaxolone, EPX-100 (Clemizole HCl), STK-001, ZX008 (Fenfluramine Hydrochloride), GWP42003-P, Soticlestat, LP352, and others

*
The Dravet Syndrome epidemiology based on gender analyzed that more men than women have Dravet Syndrome

*
The Dravet Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dravet Syndrome pipeline products will significantly revolutionize the Dravet Syndrome market dynamics.

Dravet Syndrome Overview

Dravet syndrome, also known as severe myoclonic epilepsy of infancy (SMEI), is a rare and severe form of epilepsy that begins in infancy or early childhood. It is characterized by prolonged seizures, often triggered by fever, along with other types of seizures such as myoclonic, atonic, and absence seizures.

Get a Free sample for the Dravet Syndrome Market Report:

https://www.delveinsight.com/report-store/dravet-syndrome-market [https://www.delveinsight.com/report-store/dravet-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dravet Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dravet Syndrome Epidemiology Segmentation:

The Dravet Syndrome market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Dravet Syndrome

*
Prevalent Cases of Dravet Syndrome by severity

*
Gender-specific Prevalence of Dravet Syndrome

*
Diagnosed Cases of Episodic and Chronic Dravet Syndrome

Download the report to understand which factors are driving Dravet Syndrome epidemiology trends @ Dravet Syndrome Epidemiology Forecast [https://www.delveinsight.com/sample-request/dravet-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dravet Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dravet Syndrome market or expected to get launched during the study period. The analysis covers Dravet Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dravet Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dravet Syndrome Therapies and Key Companies

*
TAK-935 (soticlestat): Takeda

*
BELVIQ (lorcaserin): Eisai

*
STK-001: Stoke Therapeurtics

*
EPX-100: EpyGenix Therapeutics

*
ganaxolone: Marinus Pharmaceuticals

*
EPX-100 (Clemizole HCl): Epygenix

*
STK-001: Stoke Therapeutics, Inc

*
ZX008 (Fenfluramine Hydrochloride): Zogenix International Ltd, Inc.

*
Soticlestat: Takeda

*
GWP42003-P: Jazz Pharmaceuticals

*
Soticlestat: Ovid Therapeutics Inc.

*
LP352: Longboard Pharmaceuticals

Discover more about therapies set to grab major Dravet Syndrome market share @ Dravet Syndrome Treatment Market [https://www.delveinsight.com/sample-request/dravet-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dravet Syndrome Market Strengths

*
The researchers are undergoing advancement in already approved drugs by providing an alternative means of delivering the drug.

*
A broader awareness among health care providers and the public for better treatments helps to improve care and outcomes.

*
Development of long-acting injectable Antipsychotics.

Dravet Syndrome Market Opportunities

*
Demands of advanced therapeutics and presence of significant number of pipeline drugs.

*
There is growing evidence that patients with a dual diagnosis does not respond well to conventional psychiatric treatment, creating demand for a new approach from a different perspective.

*
Because of the increase in the side effects and less efficacious drug, the demand for specific therapy also increases.

Scope of the Dravet Syndrome Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*

*
Key Dravet Syndrome Therapies: TAK-935 (soticlestat), BELVIQ (lorcaserin), STK-001, ganaxolone, EPX-100 (Clemizole HCl), STK-001, ZX008 (Fenfluramine Hydrochloride), GWP42003-P, Soticlestat, LP352, and others

*
Dravet Syndrome Therapeutic Assessment: Dravet Syndrome current marketed and Dravet Syndrome emerging therapies

*
Dravet Syndrome Market Dynamics: Dravet Syndrome market drivers and Dravet Syndrome market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Dravet Syndrome Unmet Needs, KOL's views, Analyst's views, Dravet Syndrome Market Access and Reimbursement

To know more about Dravet Syndrome companies working in the treatment market, visit @ Dravet Syndrome Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/dravet-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Dravet Syndrome Market Report Introduction

2. Executive Summary for Dravet Syndrome

3. SWOT analysis of Dravet Syndrome

4. Dravet Syndrome Patient Share (%) Overview at a Glance

5. Dravet Syndrome Market Overview at a Glance

6. Dravet Syndrome Disease Background and Overview

7. Dravet Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Dravet Syndrome

9. Dravet Syndrome Current Treatment and Medical Practices

10. Dravet Syndrome Unmet Needs

11. Dravet Syndrome Emerging Therapies

12. Dravet Syndrome Market Outlook

13. Country-Wise Dravet Syndrome Market Analysis (2020-2034)

14. Dravet Syndrome Market Access and Reimbursement of Therapies

15. Dravet Syndrome Market Drivers

16. Dravet Syndrome Market Barriers

17. Dravet Syndrome Appendix

18. Dravet Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dravet-syndrome-market-expected-to-experience-major-growth-by-2034-according-to-delveinsight-takeda-eisai-stoke-therapeutics-epygenix-therapeutic-marinus-pharma-stoke-therapeutics-jazz-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.